Corporate
Profile

Failed to register as Favorite Page
Failed to cancel as Favorite Page
This page is already registered as a Favorite Page
You can't add your company to your favorites.

Latest update: 27/04/2017 14:21:52

Kringle Pharma Co., Ltd.

We are a startup born from Osaka University taking on the challenge of pharmaceutical discovery and development for intractable diseases such as spinal cord injury and ALS.

Our company is a biotechnology startup born from Osaka University. We actively promote clinical discovery and development of pharmaceuticals for intractable neurological diseases, of which spinal cord injury and amyotrophic lateral sclerosis (ALS) are representative examples. We are the only company in the world that has established a good manufacturing practice (GMP) system for recombinant human hepatocyte growth factor (HGF) protein. We are specifically promoting the clinical development of recombinant human HGF protein. We aim to license the development and sales rights to pharmaceutical companies after confirming its effectiveness in human subjects.

Inquiry

Other presentation

[Company strength]
We are a biotechnology startup for drug discovery born from Osaka University. We have established a GMP manufacturing system for recombinant human HGF protein. We conduct clinical tests (trials) in Japan and abroad. We have an efficient, compact business system run by people experienced in pharmaceutical manufacturing and overseas business.

[Business description]
Our company commercializes new pharmaceuticals to save patients suffering from intractable diseases around the world through R&D of hepatocyte growth factor (HGF) pharmaceuticals. We promote the clinical development of recombinant human HGF protein. We aim to license the development and sales rights to pharmaceutical companies after confirming its effectiveness on human subjects.

[Industry]
Pharmaceutical development

[Strength of products/technologies]
HGF has the potential for use in groundbreaking pharmaceuticals for intractable diseases that cannot be treated with any drugs that are now on the market. We are the only company in the world that has established a GMP system for recombinant HGF protein. Our company is now actively tackling clinical development of pharmaceuticals applicable to representative intractable neurological diseases like acute-stage spinal cord injury as well as amyotrophic lateral sclerosis (ALS).

[Representative's message]
We are a biotechnology startup born from Osaka University. The human body naturally includes HGF, and we make use of its various functions to develop pharmaceuticals for intractable diseases that cannot currently be treated by any remedies. We hope to develop pharmaceuticals from HGF to provide groundbreaking pharmaceuticals for patients throughout in the world who are suffering from diseases. This seed for drug discovery was born in in Japan. We are doing our best all the time to achieve this wish as soon as possible. We will appreciate your support.

[Company structure for market development/overseas expansion]
Our business development department has made contact with huge overseas pharmaceutical companies and specialty pharmaceutical manufacturers. A former manager of the legal affairs department of a major pharmaceutical manufacturer and former staff member in charge of overseas business development act as advisors to this department. They can conduct license negotiations and conclude contracts in English. Our company will start full-scale negotiations as soon as the effectiveness of our products on human subjects is confirmed while we continue to update the progress of clinical trials.



[Market share/Ranking]
ALS (spinal cord injury) is an intractable neurological disease with a high demand for medical care, but for which there are no effective therapies. We aim to develop a new market with HGF pharmaceuticals.

[Awards and media coverage]
[Awards]
The 6th Japan Bio-Venture Award (October 2009).

[Media]
Nihon Keizai Shimbun and other major newspapers; Nikkei Biotechnology and Business, Yakuji Nippo, and so on.


[Authorization/Certification]
Fast Track designation from the U.S. FDA concerning the development of HGF for acute renal failure (July 2009).

[Joint research and development]
We have had a tie-up with Nippon Zenyaku Kogyo, and conducted joint research with Osaka University, Kanazawa University, Tohoku University, and Keio University. We have received official financial assistance from: AMED Development Project for Results of Research in the Medical Field, Support Program for Optimal Development of Research Result (formerly JST A-STEP); AMED Practical Research Project for Rare and Intractable Diseases (formerly Health Labour Sciences Research Grant); and NEDO Innovation Commercialization Venture Support Project 2013.

This company is recommended by the following support organizations.

Kansai Head Office, SMRJ
Inquiry